We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published In : Mar 2018
  • Code : CMI1373
  • Pages :180
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Alzheimer’s Drugs Market - Young Prospect for Aging Patient

Alzheimer’s is a form of dementia, which affect behavior, thinking, and memory of patient. The progression of disease is slow and it degrades neurons associated with learning part of cerebrum. It is most common and largest form of dementia (more than 60%), which is observed in people of age 65 and above. Accumulation of protein called as beta amyloid in spaces between nerve cells due to genetic mutation is major cause of Alzheimer. Although Alzheimer’s disease is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop treatment centered on the role of beta-amyloid in Alzheimer’s disease.

The global Alzheimer’s drugs market was valued at US$ 7 billion in 2016 and is expected to witness a CAGR of 9.5% over the forecast period (2017 - 2025).

Figure 1. Global Alzheimer’s Drugs Market (US$ Bn), by Region, 2016

alzheimer's drugs market

To learn more about this report, request a free sample copy

Source: Coherent Market Insights

Increasing prevalence of Alzheimer’s disease to drive growth of the Alzheimer’s drugs market worldwide

Increasing prevalence and incidence of Alzheimer’s disease worldwide is expected to drive the growth of Alzheimer’s disease therapeutics market. According to World Alzheimer Report in 2016, an estimated 46.5 million people were suffering from Alzheimer’s disease and the number is projected to reach 50 million by 2017, every three second there is new patient of Alzheimer’s disease worldwide.

Increasing age and aging global population are major risk factors for Alzheimer’s, which increase the disease incidence and provide growth opportunity for Alzheimer’s treatment market. For instance, according to World Population Prospects (WPP) published by United Nations in 2017, an estimated 962 million people are of age 60 or above, which accounted for 13 per cent of the global population. The number is projected to reach 1.4 billion by 2030, growing with annual rate of 3 percent. Europe currently has highest geriatric population (25% of population), Asia Pacific had geriatric population of 547 million people and it is projected to reach 900 million by 2025, therefore these regions have potential opportunity for growth of the market. India has more than 1 million cases of Alzheimer’s disease annually. North America holds dominant position in the Alzheimer’s disease therapeutics market with estimated 5.5. Mn patients in 2017. The robust healthcare infrastructure in the region, and the region being an early adopter of novel technologies, positions it as a major market for Alzheimer’s disease.

Large number of undiagnosed patient’s and revised diagnostic guidelines to propel growth for Alzheimer’s drugs market

People suffering from early stage of Alzheimer’s disease with some dementia do not have appropriate access to the healthcare infrastructure to diagnose and treat the disease. For instance according to World Alzheimer Report in 2016, only around 50% patients suffering from dementia undergo diagnosis. The rate of underdiagnoses is 10% in low and middle income economies, therefore, this is expected to propel growth of Alzheimer’s drugs market. As of 2011, there were no standard guidelines for diagnosis of disease. Currently, biomarker tests involving amount of beta-amyloid in the brain, which can be visualized in positron emission tomography imaging are under research to diagnosis develop treatment for Alzheimer’s disease. Currently, there is no curative therapy available for Alzheimer’s disease. However, drugs for Alzheimer’s therapy are in pipeline, which are expected to launch in near future, which in turn is propelling growth of Alzheimer’s disease therapeutics market.

Key players operating in Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other prominent players whose products are under clinical trials are Eli Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.

Frequently Asked Questions

The global Alzheimer’s drugs market is estimated to surpass US$ 15 Billion by 2025.

Major players operating in the global Alzheimer’s drugs market include Pfizer, Inc., Janssen Pharmaceutical, Novartis International AG, Eisai Co. Ltd., Lundbeck A/S and Teva Pharmaceuticals Industries Ltd., Other prominent players whose products are under clinical trials are Eli Lilly and Company, TauRx Pharmaceuticals Ltd, VTV Therapeutics, Hoffman-La Roche Ltd., AstraZeneca plc, and AC Immune.

Increasing prevalence and incidence of Alzheimer’s disease worldwide is one of the major factors that is influencing the adoption of Alzheimer’s drugs globally.

Rising prevalence and incidence of Alzheimer’s disease globally, coupled with improved diagnostics and development of novel drugs are some of the major factors that are expected to propel growth of the market over the forecast period.

The global Alzheimer’s drugs market is estimated to exhibit a CAGR of 9.5% over the forecast period.

Among regions, North America held dominant position in the global Alzheimer’s drugs market in 2016.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo